Multicell Techs Inc (MCET) 0.0003 $MCET Fatigue Market

New Post Public Reply Private Reply Replies (0) Message Board

Jun 9, 2016 at 8:05 AM

Multicell Techs Inc (MCET) 0.0003 $MCET

Fatigue Market Pipeline H1 2016 Global Research Report
PR Newswire - Tue Apr 05, 5:00AM CDT
New market research titled "Fatigue - Pipeline Review, H1 2016" is a report that provides an overview of worldwide Fatigue therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Global Fatigue Pipeline Review 2015 - 6 Companies & 5 Drug Profiles
M2 - Fri Sep 04, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s5t3hc/fatigue) has announced the addition of the "Fatigue - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biovista Inc. - Dimerix Bioscience Pty Ltd - Hemispherx Biopharma, Inc. - Merz Pharmaceuticals GmbH - MultiCell Technologies, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles - (lofepramine hydrochloride phenylalanine) - armodafinil - DMX-400 - MRZ-9547 - rintatolimod - Small Molecule for Chronic Fatigue Syndrome For more information visit http://www.researchandmarkets.com/research/s5t3hc/fatigue
TEVA: 53.99 (-0.07)

Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
Marketwired - Wed Jun 03, 11:30AM CDT
Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.

MultiCell Immunotherapeutics And Oxis Biotech Sign Antibody-Drug Conjugate R&D, Product License And Commercialization Agreement
PR Newswire - Thu Mar 12, 9:35AM CDT
MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc. (OTC: MCET) announced today it has signed a research & development and product license agreement with Oxis Biotech, Inc. (OXIS) to create three novel antibody-drug conjugates (ADCs) containing OXIS' lead drug candidates using MCIT's proprietary ADC platform technology. These ADC product candidates are to be used by OXIS for the treatment of triple-negative breast cancer, and multiple myeloma and associated osteolytic lesions which are significant unmet medical needs.

MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application
PR Newswire - Wed Dec 10, 7:40AM CST
MultiCell Technologies, Inc. (OTC: MCET) has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody.

Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.66 (-0.22), AMGN: 158.00 (-0.89), RGLS: 5.31 (-0.15), LLY: 74.91 (+0.21), GSK: 42.51 (-0.19), PVCT: 0.38 (-0.03), CANF: 2.95 (-0.02), DCTH: 0.26 (unch), NVS: 81.39 (-0.22), XLRN: 36.16 (+0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ServiceTitan Faces Investor Fury: Revenue Surprise

A Crippling Blow for ServiceTitan Investors When you're in the investing game long enough, you start to recognize the scent of trouble before it even hits the fan. In the case of ServiceTitan, Inc. (NASDAQ: TTAN), the smell came wafting in strong when the stock took a nosedive on September 9, 2026. Investors were left clutching their portfolios with bewilderment as shares...

Envision Tianji Dominates AI Weather Quest, Sets New Bar

Unveiling a Meteorological Masterpiece Envision's Tianji model just took the weather forecasting world by storm, quite literally. This Shanghai-based green tech giant clinched first place in the recent AI Weather Quest organized by the prestigious European Centre for Medium-Range Weather Forecasts (ECMWF). Beating out nearly 20 top-tier teams, Tianji didn't just win—it...

European Doctors Explore Chinese Aesthetic Innovations

Pioneering Exchange in Regenerative Aesthetics Ever seen European doctors flocking to China to learn about beauty techniques? That's the scene as aphranel®, the brainchild of MOYOM Biotech, ushers in a week-long clinical exchange under 'The Norns' Weave.' The whole deal aims to unravel how Chinese practices could shape Europe's aesthetic landscape. Yep, it's all about...

Duolingo Lawsuit Looms Over Securities Allegations

Duolingo Lawsuit: A New Headache for Investors Seems like every time you blink, another tech darling is getting dragged to court, and now it's Duolingo's turn to face the music. They're locked in a class action lawsuit food-fight over violations of the Securities Exchange Act of 1934, specifically, §§10(b) and 20(a), and Rule 10b-5. The Core of Allegations Against...

Wood Partners Expands Charlotte Footprint with New Project

Charlotte's Expansion Beckons New Development at Village Park Charlotte's skyline is about to get a new neighbor in a growing district, as Wood Partners is set to break ground yet again, unveiling its ambitious plans for Village Park. This is not just a hodgepodge construction talk—it’s the company’s latest effort to plant its flag deep in the heart of the Queen...

Hisense's RGB MiniLED TVs: Redefining Halloween Viewing

A New Dimension to Halloween's Visuals You ever notice how some TVs just can’t do justice to a Halloween flick? It’s all about the details—those rich, spooky colors and the perfectly balanced light and shadow. The nuance in the shadowy folds of a cape or the eerie glow of a lantern is crucial. Hisense's RGB MiniLED technology is showing up just in time to rescue...

Merchant of Tennis Data Breach Settlement Details Revealed

Settlement Reached in Data Breach Case Straight talk today about some pocketbook matters, folks. There's a class action settlement on the table for the Merchant of Tennis cyberattack crowd, and it's catching some eyes. The case stems from a 2024 hack on Merchant of Tennis, and a few other sibling companies, where sensitive files took a hike. Nobody’s fessing up to...

Tampa General Elevates Lokenauth to CFO Amid Growth

Charting New Waters at Tampa General Out here in the blue, the tides of healthcare can swell mighty quick. That's where Tampa General Hospital keeps its anchor firm, announcing Lijah Lokenauth's leap to Executive VP and CFO. If you ask me, it's all about keeping the ship steady—this fella's been steering their financial boat through some hefty waves since 2018....

Xerox Faces Probes After $130M Profit Forecast Slash

When the Trust Breaks October 29, 2026 was a gut punch for Xerox investors. Watching the outlook dive by $130 million, the coffee-feeling in the trading rooms turned into something more bitter. A $105 million boost they once celebrated from tariff receivables now seems to be a fleeting shadow, as Xerox itself scuttles its adjusted operating income for 2026 to a range of...

Navigating Hail Damage Insurance Claims as a Homeowner

Scrutinizing Hail Damage for Clarity Hailstorms can be nature's way of throwing a curveball at homeowners, especially when you least expect it. You might look out the window, see some roof shingles on the lawn, and think, 'Well, that's just great.' The aftermath of a hailstorm can be daunting and disconcerting, but having a game plan can shift things in your favor. Let's...